Merck KGaA Strengthens Anticancer Pipeline With Novel EGFR-Targeted Antibody Combination

A mixture of two antibodies that may have a novel synergistic effect against EGFR-expressing tumors has been licensed to Merck KGaA for development worldwide by Denmark's Symphogen, the recipient back in 2011 of one of the largest ever VC-backed financing rounds in Europe.